Skip to content
Screener

Ardelyx ARDX Pre-Tax Income

Pre-Tax Income at other companies

Amgen logo
AmgenAMGN
$2.77B+76.5%
Bausch Health Companies logo
Bausch Health CompaniesBHC
-$1.35B-2,781%
Ironwood Pharmaceuticals logo
Ironwood PharmaceuticalsIRWD
$73.73M+94.9%
AbbVie logo
AbbVieABBV
$4.28B+175%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$1.57M+205%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$246.8M+1,579%

Segments

By segment

See full
Reportable Segment-$12.43M+13.7%

Other financials

Income statement

See full
Revenue$120.9M+23.8%
Gross profit$115.1M+35.0%
Operating income-$12.4M+13.7%
Net income-$16.7M+12.4%
EPS (diluted)-$0.07+12.5%

Balance sheet

See full
Cash & equivalents$97.2M+7.9%
Total debt$256.2M+24.0%
Total equity$149.0M+6.8%
Total assets$575.9M+23.4%

Cash flow

See full
Operating cash flow-$6.4M+74.7%
CapEx$13.0K-98.0%
Free cash flow-$6.4M+75.3%

Valuation

See full
Market cap$1.2B-4.0%
Enterprise value$1.36B-0.6%
P/S2.7×-0.6×

Profitability

See full
Gross margin94.4%+9.6pp
Operating margin-25.4%
Net margin-12.4%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-38.6%
Debt / equity1.7×+0.2×
Current ratio3.3×-1.0×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Ardelyx’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001437402-26-000044
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Interest expense(4,957)(4,356)(10,556)(8,547)
Non-cash interest expense related to the sale of future royalties(1,267)(2,219)(2,584)(4,290)
Other income, net2,0381,8924,1504,218
Loss before provision for income taxes(16,611)(19,078)(54,208)(59,363)
Provision for income taxes1101118860
Net loss$(16,721)$(19,079)$(54,326)$(60,223)
Net loss per share of common stock - basic and diluted$(0.07)$(0.08)$(0.22)$(0.25)
Shares used in computing net loss per share - basic and diluted248,067,253239,928,570246,967,275239,279,962

Item 1. Financial Statements (Unaudited)

FAQ

What is Ardelyx's pre-tax income?
Ardelyx (ARDX) reported pre-tax income of -$16.61M in Q2 2026.
How has Ardelyx's pre-tax income changed year-over-year?
Ardelyx's pre-tax income increased by 12.9% year-over-year, from -$19.08M to -$16.61M.
What is the long-term trend for Ardelyx's pre-tax income?
Over 2 years (2021 to 2025), Ardelyx's pre-tax income has grown at a -38.1% compound annual growth rate (CAGR), from -$158.16M to -$60.63M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Ardelyx's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude